Drug Utilisation Evaluation of Human Albumin Solution in Tawau Hospital, Sabah, Malaysia

N. Mazlan, Connie Vun Sie Yee, A. Mat Yusoff, Muhamad Fauzanudin Baharudin, Kim Yok Catherine Ong, Kohila Krishnan, M. F. Limun
{"title":"Drug Utilisation Evaluation of Human Albumin Solution in Tawau Hospital, Sabah, Malaysia","authors":"N. Mazlan, Connie Vun Sie Yee, A. Mat Yusoff, Muhamad Fauzanudin Baharudin, Kim Yok Catherine Ong, Kohila Krishnan, M. F. Limun","doi":"10.21315/mjps2022.20.2.8","DOIUrl":null,"url":null,"abstract":"Human albumin solution (HAS) which is available in government hospitals in Malaysia, mostly are supplied by the National Blood Centre, Ministry of Health (MOH) Malaysia. Due to the high usage of HAS, it is a strain to meet the demands nationwide. Moreover, HAS is very expensive. This study was a retrospective observational study evaluating drug utilisation of HAS in Hospital Tawau, Sabah. A name list of 61 patients who had received HAS between 6 months from 1 January to 30 June 2019 was sent for medical records tracing. Forty-eight prescriptions of HAS were evaluated and later categorised as ‘proven indications’ or ‘unproven indications’ with the aid of an internally prepared guideline. The result of this study indicates that 12 (25%) out of 48 prescriptions were for ‘unproven indications’. Possible wastage due to ‘unproven indications’ was 29 vials which were 20% of the total HAS usage in this study, estimated to cost RM7,804 (USD1,880). Major surgery with a serum albumin level of 20 g/L and above (55.2%), paracentesis with ascitic fluid removed of less than 5 L (24.1%) and hypoalbuminemia without justified comorbid or diagnosis (20.6%) being reasons for possible wastage of HAS in this study. The percentage of possible wastage of HAS reflected in this study was not as high as other published research done in other countries, mainly due to additional steps required for prescribing HAS in our facility (filling Blood Plasma Product Request Form) and also the need to obtain approval from the Director-General of MOH Malaysia if it was prescribed for other than the approved indications.","PeriodicalId":53358,"journal":{"name":"Malaysian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaysian Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21315/mjps2022.20.2.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Human albumin solution (HAS) which is available in government hospitals in Malaysia, mostly are supplied by the National Blood Centre, Ministry of Health (MOH) Malaysia. Due to the high usage of HAS, it is a strain to meet the demands nationwide. Moreover, HAS is very expensive. This study was a retrospective observational study evaluating drug utilisation of HAS in Hospital Tawau, Sabah. A name list of 61 patients who had received HAS between 6 months from 1 January to 30 June 2019 was sent for medical records tracing. Forty-eight prescriptions of HAS were evaluated and later categorised as ‘proven indications’ or ‘unproven indications’ with the aid of an internally prepared guideline. The result of this study indicates that 12 (25%) out of 48 prescriptions were for ‘unproven indications’. Possible wastage due to ‘unproven indications’ was 29 vials which were 20% of the total HAS usage in this study, estimated to cost RM7,804 (USD1,880). Major surgery with a serum albumin level of 20 g/L and above (55.2%), paracentesis with ascitic fluid removed of less than 5 L (24.1%) and hypoalbuminemia without justified comorbid or diagnosis (20.6%) being reasons for possible wastage of HAS in this study. The percentage of possible wastage of HAS reflected in this study was not as high as other published research done in other countries, mainly due to additional steps required for prescribing HAS in our facility (filling Blood Plasma Product Request Form) and also the need to obtain approval from the Director-General of MOH Malaysia if it was prescribed for other than the approved indications.
马来西亚沙巴州斗湖医院人白蛋白溶液的药物利用评价
马来西亚政府医院提供的人白蛋白溶液(HAS),主要由马来西亚卫生部(MOH)国家血液中心提供。由于HAS的高使用率,满足全国的需求是一种压力。此外,HAS非常昂贵。本研究是一项回顾性观察性研究,评估沙巴州斗湖医院HAS的药物利用情况。在2019年1月1日至6月30日6个月内接受HAS治疗的61名患者的名单已发送用于医疗记录追踪。在内部编制的指南的帮助下,对48个HAS处方进行了评估,并随后将其分类为“已证实的适应症”或“未证实的适应症”。这项研究的结果表明,48张处方中有12张(25%)用于“未经证实的适应症”。由于“未经证实的适应症”可能造成的浪费为29瓶,占本研究中HAS总使用量的20%,估计成本为7804令吉(1880美元)。在本研究中,大手术时血清白蛋白水平为20 g/L及以上(55.2%),穿刺时腹水排出量小于5 L(24.1%),以及无合理合并症或诊断的低白蛋白血症(20.6%)是可能造成HAS浪费的原因。本研究中反映的ha可能浪费的百分比并不像其他国家发表的其他研究那样高,主要是由于在我们的设施中处方ha需要额外的步骤(填写血浆产品申请表),并且如果它是针对批准适应症以外的其他适应症开出的,则需要获得马来西亚卫生部总干事的批准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
11
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信